iBio, Inc. filed a Current Report on Form 8-K dated September 14, 2026, announcing the update of its corporate presentation. The filing, filed with the U.S. Securities and Exchange Commission, states that the updated presentation is attached as Exhibit 99.1 and is intended for use in meetings with investors, analysts, and other parties.
The presentation focuses on the company's strategy for developing next-generation therapies for obesity and cardiometabolic diseases. It highlights a portfolio approach targeting multiple mechanisms to deliver treatments that improve upon the quality of weight loss achieved by first-generation incretin-based therapies.
The presentation outlines four lead programs and one partnered program. The lead programs include:
- IBIO-610: A long-acting antibody against Activin E, a liver-derived hepatokine. The company notes that loss-of-function variants in the gene encoding Activin E are linked to favorable fat distribution and lower Type 2 Diabetes risk. Preclinical data in obese non-human primates indicates the antibody achieves near-complete suppression of circulating Activin E and shows potential for greater fat loss while preserving lean mass.
- IBIO-800: A bispecific antibody targeting Myostatin and Activin A. The company anticipates an IND-equivalent filing in the first half of 2027.
- IBIO-600: A long-acting antibody targeting Myostatin. Preclinical data suggests a half-life of 52.4 days in non-human primates, potentially allowing for dosing as infrequent as twice a year. The company anticipates interim Phase 1 data in the first quarter of 2027.
- IBIO-610 (Partnered): The presentation notes a partnered program with anticipated upcoming milestones for discovery candidates in the second half of 2027.
Regarding anticipated near-term catalysts, the company expects an IND-equivalent filing for IBIO-610 in the second half of 2026 and the initiation of Phase 1 trials for IBIO-610 in the first half of 2027.
